| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 54.6 | 60.0 |
| Gross profit | 42.2 | 46.0 |
| Profit before tax | -5.9 | -17.3 |
| Net income | -3.9 | -14.8 |
| EPS (diluted, $ a share) | $-0.04 | $-0.14 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -9.0% |
|---|---|
| Gross margin | 77.3% |
| Operating margin | -9.1% |
10-Q filed with the SEC, NASDAQ: DH. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Definitive Healthcare Corp.: key numbers
- Share price
- $1.31Close, Nov 17
- Market cap
- $140M
- Shares outstanding
- 107.16MLatest SEC cover page
- Sector
- Technology
- Industry
- Services-Prepackaged SoftwareSIC 7372
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Definitive Healthcare Corp.
All →Definitive Healthcare Financial Results
Definitive Healthcare reported Q3 2026 revenue of $54.7 million, a 9% decrease year-over-year, while narrowing its net loss to $5.4 million. The company noted it will not provide forward guidance or host an earnings call due to a pending non-binding acquisition proposal from Advent International.
- Term
- Q3 2026
“Since joining Definitive, I’ve been focused on listening to our customers and our employees. What I’ve heard confirms my belief in the strength of our position in the market, and it has also shown me where we can execute better. This quarter’s results demonstrate the underlying health of the business and a solid foundation to build upon.”
Clay Ritchey, CEO of Definitive Healthcare